{"protocolSection": {"identificationModule": {"nctId": "NCT02219048", "orgStudyIdInfo": {"id": "A9111007"}, "secondaryIdInfos": [{"id": "INHALED P38I ASTHMA", "type": "OTHER", "domain": "Alias Study Number"}], "organization": {"fullName": "Pfizer", "class": "INDUSTRY"}, "briefTitle": "An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled Asthma", "officialTitle": "A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-03715455 ADMINISTERED TWICE DAILY BY INHALATION FOR 12 WEEKS IN SUBJECTS WITH PERSISTENT MODERATE TO SEVERE ASTHMA WHO REMAIN UNCONTROLLED DESPITE TREATMENT WITH INHALED CORTICOSTEROIDS (ICS) AND LONG-ACTING BETA2 AGONISTS (LABA)"}, "statusModule": {"statusVerifiedDate": "2019-05", "overallStatus": "TERMINATED", "whyStopped": "The termination was due to business reasons. No safety or efficacy concerns contributed to the termination of the study", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-11", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2015-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-08-14", "studyFirstSubmitQcDate": "2014-08-14", "studyFirstPostDateStruct": {"date": "2014-08-18", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-04-12", "resultsFirstSubmitQcDate": "2019-05-23", "resultsFirstPostDateStruct": {"date": "2019-06-12", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-05-23", "lastUpdatePostDateStruct": {"date": "2019-06-12", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Pfizer", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The study proposes to evaluate the safety and efficacy of PF-03715455 in moderate to severe asthma when added to standard of care and during staged withdrawal of background therapy.", "detailedDescription": "Study terminated on 7th April 2015. The termination was due to business reasons. No safety or efficacy concerns contributed to the termination of the study"}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma", "Staged withdrawal of background therapy"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 51, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Matched blinded placebo", "interventionNames": ["Drug: Placebo"]}, {"label": "PF-03715455", "type": "EXPERIMENTAL", "description": "PF-03715455", "interventionNames": ["Drug: PF-03715455"]}], "interventions": [{"type": "DRUG", "name": "Placebo", "description": "680 micrograms BID, Orally inhaled placebo for 12 weeks", "armGroupLabels": ["Placebo"]}, {"type": "DRUG", "name": "PF-03715455", "description": "680 micrograms BID, Orally inhaled PF-03715455 for 12 weeks", "armGroupLabels": ["PF-03715455"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percentage of Participants With Asthma Worsening Events", "description": "Asthma worsening was defined as one of the following events: greater than or equal to (\\>=) 30% reduction from baseline in morning peak expiratory flow (PEF) on 2 consecutive days; \\>=6 additional rescue puffs of albuterol or levalbuterol in a 24-hour period (compared to baseline) on 2 consecutive days; deterioration of asthma (as determined by the Investigator) requiring systemic steroid treatment, an increase in inhaled corticosteroids \\>=4 times the last dose received prior to discontinuation from the study, or hospitalization due to asthma.", "timeFrame": "Baseline up to follow-up period (Week 16)"}], "secondaryOutcomes": [{"measure": "Time to Asthma Worsening Event", "description": "The time post randomization that the first asthma worsening event occurred (defined above).", "timeFrame": "Baseline up to follow-up period (Week 16)"}, {"measure": "Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)", "description": "FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Baseline was defined as the latest measurement before first dosing.", "timeFrame": "Baseline, Week 1, Week 2, Week 3, and Week 4"}, {"measure": "Change From Baseline in Forced Vital Capacity (FVC)", "description": "FVC is the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible.", "timeFrame": "Baseline, Week 1, Week 2, Week 3, and Week 4"}, {"measure": "Change From Baseline in Forced Expiratory Volume in 6 Seconds (FEV6)", "description": "FEV6 is the maximal volume of air exhaled in the first 6 seconds of a forced expiration from a position of full inspiration.", "timeFrame": "Baseline, Week 1, Week 2, Week 3, and Week 4"}, {"measure": "Change From Baseline in Asthma Symptom Scores", "description": "Participants used a daily diary assessment to record overall asthma symptom scores twice a day (morning and evening). Questions included extent of albuterol use, symptoms of wheezing, breathlessness, chest tightness, and cough. The visit dependent asthma symptom scores were calculated based on the item in the daily diary assessment. A participant summarized her/his daily frequency of asthma symptoms during the last 24 hours by the assignment of an integer score (0,1,2,3 or 4). The score=0 value denoted the day without symptoms and the score=4 value denoted the day where symptoms occurred all of the time. The asthma symptom scores were calculated by averaging the values of the daily scores within visit-dependent time window. Higher score indicates asthma worsening", "timeFrame": "Baseline, Week 1, Week 2, Week 3, and Week 4"}, {"measure": "Number of Night Time Awakenings Per Week", "description": "The number of nocturnal awakenings due to asthma symptoms was recorded by the participant.", "timeFrame": "Baseline, Week 1, Week 2, Week 3, and Week 4"}, {"measure": "Change From Baseline in Morning and Evening Peak Expiratory Flow (PEF)", "description": "The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. The changes from baseline (CFB) at each week and over 4 weeks were analyzed.", "timeFrame": "Baseline, Week 1, Week 2, Week 3, and Week 4"}, {"measure": "Change From Baseline in Asthma Control Questionnaire (ACQ)-5 Score at Week 1, Week 2, Week 3, and Week 4", "description": "The 5-question version of the Juniper ACQ is a validated questionnaire to evaluate asthma control. Questions were weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The mean ACQ score was the mean of the responses. Mean scores of \\<= 0.75 indicate well-controlled asthma, scores between 0.76 and less than (\\<) 1.5 indicate partly controlled asthma, and a score \\>= 1.5 indicates uncontrolled asthma.", "timeFrame": "Baseline, Week 1, Week 2, Week 3, and Week 4"}, {"measure": "Number of Daily Puffs of Rescue Medication", "description": "The use of rescue bronchodilators (albuterol or levalbuterol) for symptomatic relief of asthma in a 24-hour period was recorded by the participant.", "timeFrame": "Baseline, Week 1, Week 2, Week 3, and Week 4"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Subjects with a physician documented history or diagnosis of persistent asthma (according to GINA, 2014 definition of asthma),\n* Pre bronchodilator FEV1 of greater than or equal to 50 and less that 80% of predicted.\n* Subjects defined as GINA Step 4 on a stable dose of either fluticasone/salmeterol combination therapy, or budesonide/formoterol combination therapy or mometasone/formoterol combination therapy.\n* Subjects who are defined as uncontrolled as evidenced by; Juniper Asthma Control Questionnaire (5 item version, ACQ) score greater than or equal to 1.5 and less than or equal to 3.0)\n\nExclusion Criteria:\n\n* Subjects diagnosed with chronic pulmonary disease (COPD) and/or other chronic pulmonary diseases (eg, Occupational asthma, pulmonary fibrosis, bronchiectasis, Allergic bronchopulmonary aspergillosis (ABPA), pneumoconiosis, sarcoidosis, tuberculosis).\n* Subjects who are current smokers.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Pfizer CT.gov Call Center", "affiliation": "Pfizer", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Clinical Research Center of Alabama", "city": "Birmingham", "state": "Alabama", "zip": "35209", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "Pulmonary Associates, Pa", "city": "Phoenix", "state": "Arizona", "zip": "85006", "country": "United States", "geoPoint": {"lat": 33.44838, "lon": -112.07404}}, {"facility": "Little Rock Allergy & Asthma Clinical Research Center", "city": "Little Rock", "state": "Arkansas", "zip": "72205-4565", "country": "United States", "geoPoint": {"lat": 34.74648, "lon": -92.28959}}, {"facility": "California Research Medical Group, Inc", "city": "Fullerton", "state": "California", "zip": "92835", "country": "United States", "geoPoint": {"lat": 33.87029, "lon": -117.92534}}, {"facility": "California Allergy and Asthma Medical Group, Inc.", "city": "Los Angeles", "state": "California", "zip": "90025", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Jonathan Corren MD, Inc.", "city": "Los Angeles", "state": "California", "zip": "90025", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Integrated Research Group, Incorporated", "city": "Riverside", "state": "California", "zip": "92506", "country": "United States", "geoPoint": {"lat": 33.95335, "lon": -117.39616}}, {"facility": "Peninsula Research Associates", "city": "Rolling Hills Estates", "state": "California", "zip": "90274", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -118.35813}}, {"facility": "Allergy Associates Medical Group", "city": "San Diego", "state": "California", "zip": "92108", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "Asthma and Allergy Associates, PC", "city": "Colorado Springs", "state": "Colorado", "zip": "80907", "country": "United States", "geoPoint": {"lat": 38.83388, "lon": -104.82136}}, {"facility": "Colorado Allergy and Asthma Centers, PC", "city": "Denver", "state": "Colorado", "zip": "80230", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "University of South Florida - Asthma, Allergy and Immunology Clinical Research Unit", "city": "Tampa", "state": "Florida", "zip": "33613", "country": "United States", "geoPoint": {"lat": 27.94752, "lon": -82.45843}}, {"facility": "Florida Pulmonary Research Institute, LLC", "city": "Winter Park", "state": "Florida", "zip": "32789", "country": "United States", "geoPoint": {"lat": 28.6, "lon": -81.33924}}, {"facility": "Chesapeake Clinical Research, Inc.", "city": "Baltimore", "state": "Maryland", "zip": "21236", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "Northeast Medical Research Associates, Inc.", "city": "North Dartmouth", "state": "Massachusetts", "zip": "02747", "country": "United States", "geoPoint": {"lat": 41.63899, "lon": -70.97032}}, {"facility": "Clinical Research Institute", "city": "Minneapolis", "state": "Minnesota", "zip": "55402", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "Washington University School of Medicine", "city": "Saint Louis", "state": "Missouri", "zip": "63110", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Associated Specialists in Medicine, PC", "city": "Saint Louis", "state": "Missouri", "zip": "63141", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "The Clinical Research Center, L.L.C.", "city": "Saint Louis", "state": "Missouri", "zip": "63141", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "The Asthma and Allergy Center", "city": "Bellevue", "state": "Nebraska", "zip": "68123", "country": "United States", "geoPoint": {"lat": 41.13667, "lon": -95.89084}}, {"facility": "North Shore Long Island Jewish Health System", "city": "New Hyde Park", "state": "New York", "zip": "11040", "country": "United States", "geoPoint": {"lat": 40.7351, "lon": -73.68791}}, {"facility": "American Health Research", "city": "Charlotte", "state": "North Carolina", "zip": "28277", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "Wake Forest University School of Medicine", "city": "Winston-Salem", "state": "North Carolina", "zip": "27103", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "Bernstein Clinical Research Center", "city": "Cincinnati", "state": "Ohio", "zip": "45231", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "University of Pittsburgh Asthma Institute", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15213", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Upstate Pharmaceutical Research", "city": "Greenville", "state": "South Carolina", "zip": "29615", "country": "United States", "geoPoint": {"lat": 34.85262, "lon": -82.39401}}, {"facility": "The Allergy & Asthma Clinic of Central Texas", "city": "Killeen", "state": "Texas", "zip": "76542", "country": "United States", "geoPoint": {"lat": 31.11712, "lon": -97.7278}}, {"facility": "University of Wisconsin School of Medicine & Public Health", "city": "Madison", "state": "Wisconsin", "zip": "53792", "country": "United States", "geoPoint": {"lat": 43.07305, "lon": -89.40123}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "To obtain contact information for a study center near you, click here.", "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A9111007&StudyName=An%20Evaluation%20Of%20PF-03715455%20In%20Moderate%20To%20Severe%20Uncontrolled%20Asthma"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.", "url": "https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Placebo Twice Daily", "description": "Participants received placebo-matched PF-03715455 twice a day for 12 weeks via oral inhalation using the Miat monodose inhaler."}, {"id": "FG001", "title": "PF-03715455 680 mcg Twice Daily", "description": "Participants received PF-03715455 680 micrograms (mcg) twice a day for 12 weeks via oral inhalation using the Miat monodose inhaler."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "26"}, {"groupId": "FG001", "numSubjects": "25"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "21"}, {"groupId": "FG001", "numSubjects": "21"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "No longer meets eligibility criteria", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Study terminated by sponsor", "reasons": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "15"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "The baseline analysis population included all randomized participants who received at least 1 dose of PF-03715455 or placebo.", "groups": [{"id": "BG000", "title": "Placebo Twice Daily", "description": "Participants received placebo-matched PF-03715455 twice a day for 12 weeks via oral inhalation using the Miat monodose inhaler."}, {"id": "BG001", "title": "PF-03715455 680 mcg Twice Daily", "description": "Participants received PF-03715455 680 micrograms (mcg) twice a day for 12 weeks via oral inhalation using the Miat monodose inhaler."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "26"}, {"groupId": "BG001", "value": "25"}, {"groupId": "BG002", "value": "51"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "42.3", "spread": "14.1"}, {"groupId": "BG001", "value": "44.2", "spread": "10.0"}, {"groupId": "BG002", "value": "43.2", "spread": "12.2"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "28"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "23"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percentage of Participants With Asthma Worsening Events", "description": "Asthma worsening was defined as one of the following events: greater than or equal to (\\>=) 30% reduction from baseline in morning peak expiratory flow (PEF) on 2 consecutive days; \\>=6 additional rescue puffs of albuterol or levalbuterol in a 24-hour period (compared to baseline) on 2 consecutive days; deterioration of asthma (as determined by the Investigator) requiring systemic steroid treatment, an increase in inhaled corticosteroids \\>=4 times the last dose received prior to discontinuation from the study, or hospitalization due to asthma.", "populationDescription": "The modified intent-to-treat (mITT) analysis set included all randomized participants who received at least 1 dose of PF-03715455 or placebo.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline up to follow-up period (Week 16)", "groups": [{"id": "OG000", "title": "Placebo Twice Daily", "description": "Participants received placebo-matched PF-03715455 twice a day for 12 weeks via oral inhalation using the Miat monodose inhaler."}, {"id": "OG001", "title": "PF-03715455 680 mcg Twice Daily", "description": "Participants received PF-03715455 680 micrograms (mcg) twice a day for 12 weeks via oral inhalation using the Miat monodose inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "25"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "11.5"}, {"groupId": "OG001", "value": "16.0"}]}]}]}, {"type": "SECONDARY", "title": "Time to Asthma Worsening Event", "description": "The time post randomization that the first asthma worsening event occurred (defined above).", "populationDescription": "The modified intent-to-treat (mITT) analysis set initially included all randomized participants who received at least 1 dose of PF-03715455 or placebo. Only 7 participants (4 in PF-03715455 and 3 in placebo) were included in the presented descriptive analysis, since other observations were censored by study termination.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "days", "timeFrame": "Baseline up to follow-up period (Week 16)", "groups": [{"id": "OG000", "title": "Placebo Twice Daily", "description": "Participants received placebo-matched PF-03715455 twice a day for 12 weeks via oral inhalation using the Miat monodose inhaler."}, {"id": "OG001", "title": "PF-03715455 680 mcg Twice Daily", "description": "Participants received PF-03715455 680 micrograms (mcg) twice a day for 12 weeks via oral inhalation using the Miat monodose inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "4"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "58", "lowerLimit": "35", "upperLimit": "82"}, {"groupId": "OG001", "value": "19.5", "lowerLimit": "2", "upperLimit": "84"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)", "description": "FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Baseline was defined as the latest measurement before first dosing.", "populationDescription": "The mITT analysis set included all randomized participants who received at least 1 dose of PF-03715455 or placebo; n=number of participants analyzed in respective arms for category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liters", "timeFrame": "Baseline, Week 1, Week 2, Week 3, and Week 4", "groups": [{"id": "OG000", "title": "Placebo Twice Daily", "description": "Participants received placebo-matched PF-03715455 twice a day for 12 weeks via oral inhalation using the Miat monodose inhaler."}, {"id": "OG001", "title": "PF-03715455 680 mcg Twice Daily", "description": "Participants received PF-03715455 680 micrograms (mcg) twice a day for 12 weeks via oral inhalation using the Miat monodose inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "25"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "25"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.084", "spread": "0.4645"}, {"groupId": "OG001", "value": "2.158", "spread": "0.4917"}]}]}, {"title": "Change From Baseline at Week 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "25"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.188", "spread": "0.3941"}, {"groupId": "OG001", "value": "0.111", "spread": "0.2226"}]}]}, {"title": "Change From Baseline at Week 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "23"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.244", "spread": "0.3797"}, {"groupId": "OG001", "value": "0.107", "spread": "0.1959"}]}]}, {"title": "Change From Baseline at Week 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "20"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.273", "spread": "0.3444"}, {"groupId": "OG001", "value": "0.124", "spread": "0.2140"}]}]}, {"title": "Change From Baseline at Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "21"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.234", "spread": "0.3251"}, {"groupId": "OG001", "value": "0.148", "spread": "0.2217"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Change From Baseline at Week 1", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Longitudinal Analysis of Covariance", "statisticalComment": "LANCOVA model contained fixed factors of treatment, week, treatment/baseline by week interaction, baseline value, and unstructured covariance matrix.", "paramType": "Mean Difference (Net)", "paramValue": "-0.0719", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.2243", "ciUpperLimit": "0.0805", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0909"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change From Baseline at Week 2", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Longitudinal Analysis of Covariance", "statisticalComment": "LANCOVA model contained fixed factors of treatment, week, treatment/baseline by week interaction, baseline value, and unstructured covariance matrix.", "paramType": "Mean Difference (Net)", "paramValue": "-0.0920", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.2362", "ciUpperLimit": "0.0523", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0860"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change From Baseline at Week 3", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Longitudinal Analysis of Covariance", "statisticalComment": "LANCOVA model contained fixed factors of treatment, week, treatment/baseline by week interaction, baseline value, and unstructured covariance matrix.", "paramType": "Mean Difference (Net)", "paramValue": "-0.1131", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.2536", "ciUpperLimit": "0.0274", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0837"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change From Baseline at Week 4", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Longitudinal Analysis of Covariance", "statisticalComment": "LANCOVA model contained fixed factors of treatment, week, treatment/baseline by week interaction, baseline value, and unstructured covariance matrix.", "paramType": "Mean Difference (Net)", "paramValue": "-0.0580", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.1971", "ciUpperLimit": "0.0812", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0829"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change From Baseline Over Week 1 to 4", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Longitudinal Analysis of Covariance", "statisticalComment": "LANCOVA model contained fixed factors of treatment, week, treatment/baseline by week interaction, baseline value, and unstructured covariance matrix.", "paramType": "Median Difference (Net)", "paramValue": "-0.0837", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.2081", "ciUpperLimit": "0.0406", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0742"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Forced Vital Capacity (FVC)", "description": "FVC is the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible.", "populationDescription": "The mITT analysis set included all randomized participants who received at least 1 dose of PF-03715455 or placebo; n=number of participants analyzed in respective arms for category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liters", "timeFrame": "Baseline, Week 1, Week 2, Week 3, and Week 4", "groups": [{"id": "OG000", "title": "Placebo Twice Daily", "description": "Participants received placebo-matched PF-03715455 twice a day for 12 weeks via oral inhalation using the Miat monodose inhaler."}, {"id": "OG001", "title": "PF-03715455 680 mcg Twice Daily", "description": "Participants received PF-03715455 680 micrograms (mcg) twice a day for 12 weeks via oral inhalation using the Miat monodose inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "25"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "25"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.393", "spread": "0.8966"}, {"groupId": "OG001", "value": "3.384", "spread": "0.8958"}]}]}, {"title": "Change at Week 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "25"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.140", "spread": "0.3866"}, {"groupId": "OG001", "value": "0.042", "spread": "0.2401"}]}]}, {"title": "Change at Week 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "23"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.243", "spread": "0.3813"}, {"groupId": "OG001", "value": "0.066", "spread": "0.2321"}]}]}, {"title": "Change at Week 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "20"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.252", "spread": "0.3053"}, {"groupId": "OG001", "value": "0.020", "spread": "0.2784"}]}]}, {"title": "Change at Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "21"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.178", "spread": "0.3028"}, {"groupId": "OG001", "value": "0.080", "spread": "0.3136"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Forced Expiratory Volume in 6 Seconds (FEV6)", "description": "FEV6 is the maximal volume of air exhaled in the first 6 seconds of a forced expiration from a position of full inspiration.", "populationDescription": "The mITT analysis set included all randomized participants who received at least 1 dose of PF-03715455 or placebo; n=number of participants analyzed in respective arms for category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liters", "timeFrame": "Baseline, Week 1, Week 2, Week 3, and Week 4", "groups": [{"id": "OG000", "title": "Placebo Twice Daily", "description": "Participants received placebo-matched PF-03715455 twice a day for 12 weeks via oral inhalation using the Miat monodose inhaler."}, {"id": "OG001", "title": "PF-03715455 680 mcg Twice Daily", "description": "Participants received PF-03715455 680 micrograms (mcg) twice a day for 12 weeks via oral inhalation using the Miat monodose inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "25"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "25"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.175", "spread": "0.7707"}, {"groupId": "OG001", "value": "3.150", "spread": "0.7546"}]}]}, {"title": "Change at Week 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "25"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.134", "spread": "0.3782"}, {"groupId": "OG001", "value": "0.078", "spread": "0.2401"}]}]}, {"title": "Change at Week 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "23"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.221", "spread": "0.3603"}, {"groupId": "OG001", "value": "0.072", "spread": "0.1922"}]}]}, {"title": "Change at Week 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "20"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.264", "spread": "0.3149"}, {"groupId": "OG001", "value": "0.069", "spread": "0.2569"}]}]}, {"title": "Change at Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "21"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.178", "spread": "0.2986"}, {"groupId": "OG001", "value": "0.106", "spread": "0.2664"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Asthma Symptom Scores", "description": "Participants used a daily diary assessment to record overall asthma symptom scores twice a day (morning and evening). Questions included extent of albuterol use, symptoms of wheezing, breathlessness, chest tightness, and cough. The visit dependent asthma symptom scores were calculated based on the item in the daily diary assessment. A participant summarized her/his daily frequency of asthma symptoms during the last 24 hours by the assignment of an integer score (0,1,2,3 or 4). The score=0 value denoted the day without symptoms and the score=4 value denoted the day where symptoms occurred all of the time. The asthma symptom scores were calculated by averaging the values of the daily scores within visit-dependent time window. Higher score indicates asthma worsening", "populationDescription": "The mITT analysis set included all randomized participants who received at least 1 dose of PF-03715455 or placebo; n=number of participants analyzed in respective arms for category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, Week 1, Week 2, Week 3, and Week 4", "groups": [{"id": "OG000", "title": "Placebo Twice Daily", "description": "Participants received placebo-matched PF-03715455 twice a day for 12 weeks via oral inhalation using the Miat monodose inhaler."}, {"id": "OG001", "title": "PF-03715455 680 mcg Twice Daily", "description": "Participants received PF-03715455 680 micrograms (mcg) twice a day for 12 weeks via oral inhalation using the Miat monodose inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "25"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "25"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.15", "spread": "0.567"}, {"groupId": "OG001", "value": "1.23", "spread": "0.636"}]}]}, {"title": "Change at Week 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "25"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.14", "spread": "0.406"}, {"groupId": "OG001", "value": "-0.12", "spread": "0.453"}]}]}, {"title": "Change at Week 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "23"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.17", "spread": "0.497"}, {"groupId": "OG001", "value": "-0.36", "spread": "0.560"}]}]}, {"title": "Change at Week 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "20"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.15", "spread": "0.471"}, {"groupId": "OG001", "value": "-0.44", "spread": "0.458"}]}]}, {"title": "Change at Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "21"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.19", "spread": "0.565"}, {"groupId": "OG001", "value": "-0.38", "spread": "0.513"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Change From Baseline Averaged Over Week 1 to 4", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Longitudinal Analysis of Covariance", "statisticalComment": "LANCOVA model contained fixed factors of treatment, week, treatment/baseline by week interaction, baseline value, and unstructured covariance matrix.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.090", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.285", "ciUpperLimit": "0.106", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.116"}]}, {"type": "SECONDARY", "title": "Number of Night Time Awakenings Per Week", "description": "The number of nocturnal awakenings due to asthma symptoms was recorded by the participant.", "populationDescription": "The mITT analysis set included all randomized participants who received at least 1 dose of PF-03715455 or placebo; n=number of participants analyzed in respective arms for category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "night awakenings per week", "timeFrame": "Baseline, Week 1, Week 2, Week 3, and Week 4", "groups": [{"id": "OG000", "title": "Placebo Twice Daily", "description": "Participants received placebo-matched PF-03715455 twice a day for 12 weeks via oral inhalation using the Miat monodose inhaler."}, {"id": "OG001", "title": "PF-03715455 680 mcg Twice Daily", "description": "Participants received PF-03715455 680 micrograms (mcg) twice a day for 12 weeks via oral inhalation using the Miat monodose inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "25"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "25"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.03", "spread": "2.088"}, {"groupId": "OG001", "value": "1.40", "spread": "1.925"}]}]}, {"title": "Week 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "25"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.34", "spread": "2.101"}, {"groupId": "OG001", "value": "1.38", "spread": "2.210"}]}]}, {"title": "Week 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "23"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.39", "spread": "1.990"}, {"groupId": "OG001", "value": "1.43", "spread": "2.251"}]}]}, {"title": "Week 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "20"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.89", "spread": "1.657"}, {"groupId": "OG001", "value": "1.66", "spread": "2.431"}]}]}, {"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "21"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.04", "spread": "1.869"}, {"groupId": "OG001", "value": "1.27", "spread": "1.830"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Morning and Evening Peak Expiratory Flow (PEF)", "description": "The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. The changes from baseline (CFB) at each week and over 4 weeks were analyzed.", "populationDescription": "The mITT analysis set included all randomized participants who received at least 1 dose of PF-03715455 or placebo; n=number of participants analyzed in respective arms for category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liters per minute", "timeFrame": "Baseline, Week 1, Week 2, Week 3, and Week 4", "groups": [{"id": "OG000", "title": "Placebo Twice Daily", "description": "Participants received placebo-matched PF-03715455 twice a day for 12 weeks via oral inhalation using the Miat monodose inhaler."}, {"id": "OG001", "title": "PF-03715455 680 mcg Twice Daily", "description": "Participants received PF-03715455 680 micrograms (mcg) twice a day for 12 weeks via oral inhalation using the Miat monodose inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "25"}]}], "classes": [{"title": "Morning PEF: Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "25"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "346.67", "spread": "92.666"}, {"groupId": "OG001", "value": "361.46", "spread": "145.788"}]}]}, {"title": "Morning PEF: CFB at Week 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "25"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "17.42", "spread": "31.100"}, {"groupId": "OG001", "value": "22.25", "spread": "41.585"}]}]}, {"title": "Morning PEF: CFB at Week 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "23"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "22.25", "spread": "38.822"}, {"groupId": "OG001", "value": "29.80", "spread": "51.818"}]}]}, {"title": "Morning PEF: CFB at Week 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "20"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "18.86", "spread": "40.775"}, {"groupId": "OG001", "value": "23.55", "spread": "42.129"}]}]}, {"title": "Morning PEF: CFB at Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "21"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "21.54", "spread": "41.697"}, {"groupId": "OG001", "value": "22.65", "spread": "47.892"}]}]}, {"title": "Evening PEF: Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "25"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "357.86", "spread": "91.426"}, {"groupId": "OG001", "value": "382.05", "spread": "130.316"}]}]}, {"title": "Evening PEF: CFB at Week 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "25"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "20.51", "spread": "33.868"}, {"groupId": "OG001", "value": "20.14", "spread": "43.925"}]}]}, {"title": "Evening PEF: CFB at Week 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "23"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "20.70", "spread": "29.127"}, {"groupId": "OG001", "value": "23.87", "spread": "40.435"}]}]}, {"title": "Evening PEF: CFB at Week 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "20"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "22.55", "spread": "35.234"}, {"groupId": "OG001", "value": "17.74", "spread": "44.378"}]}]}, {"title": "Evening PEF: CFB at Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "21"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "19.10", "spread": "42.063"}, {"groupId": "OG001", "value": "23.22", "spread": "48.329"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Morning PEF: CFB at Week 1", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Longitudinal Analysis of Covariance", "statisticalComment": "LANCOVA model contained fixed factors of treatment, week, treatment/baseline by week interaction, baseline value, and unstructured covariance matrix.", "paramType": "Mean Difference (Final Values)", "paramValue": "6.017", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-10.760", "ciUpperLimit": "22.794", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "10.003"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Morning PEF: CFB at Week 2", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Longitudinal Analysis of Covariance", "statisticalComment": "LANCOVA model contained fixed factors of treatment, week, treatment/baseline by week interaction, baseline value, and unstructured covariance matrix.", "paramType": "Mean Difference (Final Values)", "paramValue": "6.591", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-13.926", "ciUpperLimit": "27.108", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "12.228"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Morning PEF: CFB at Week 3", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Longitudinal Analysis of Covariance", "statisticalComment": "LANCOVA model contained fixed factors of treatment, week, treatment/baseline by week interaction, baseline value, and unstructured covariance matrix.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.954", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-18.644", "ciUpperLimit": "20.552", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "11.673"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Morning PEF: CFB at Week 4", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Longitudinal Analysis of Covariance", "statisticalComment": "LANCOVA model contained fixed factors of treatment, week, treatment/baseline by week interaction, baseline value, and unstructured covariance matrix.", "paramType": "Mean Difference (Final Values)", "paramValue": "-4.368", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-26.069", "ciUpperLimit": "17.333", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "12.920"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Morning PEF: CFB Averaged Over 4 Weeks", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Longitudinal Analysis of Covariance", "statisticalComment": "LANCOVA model contained fixed factors of treatment, week, treatment/baseline by week interaction, baseline value, and unstructured covariance matrix.", "paramType": "Mean Difference (Final Values)", "paramValue": "2.299", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-15.323", "ciUpperLimit": "19.920", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "10.503"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Evening PEF: CFB at Week 1", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Longitudinal Analysis of Covariance", "statisticalComment": "LANCOVA model contained fixed factors of treatment, week, treatment/baseline by week interaction, baseline value, and unstructured covariance matrix.", "paramType": "Mean Difference (Final Values)", "paramValue": "1.135", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-17.248", "ciUpperLimit": "19.519", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "10.961"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Evening PEF: CFB at Week 2", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Longitudinal Analysis of Covariance", "statisticalComment": "LANCOVA model contained fixed factors of treatment, week, treatment/baseline by week interaction, baseline value, and unstructured covariance matrix.", "paramType": "Mean Difference (Final Values)", "paramValue": "2.834", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-13.871", "ciUpperLimit": "19.540", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "9.956"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Evening PEF: CFB at Week 3", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Longitudinal Analysis of Covariance", "statisticalComment": "LANCOVA model contained fixed factors of treatment, week, treatment/baseline by week interaction, baseline value, and unstructured covariance matrix.", "paramType": "Mean Difference (Final Values)", "paramValue": "-8.374", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-27.933", "ciUpperLimit": "11.185", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "11.652"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Evening PEF: CFB at Week 4", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Longitudinal Analysis of Covariance", "statisticalComment": "LANCOVA model contained fixed factors of treatment, week, treatment/baseline by week interaction, baseline value, and unstructured covariance matrix.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.445", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-23.245", "ciUpperLimit": "22.356", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "13.573"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Evening PEF: CFB Averaged Over 4 Weeks", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Longitudinal Analysis of Covariance", "statisticalComment": "LANCOVA model contained fixed factors of treatment, week, treatment/baseline by week interaction, baseline value, and unstructured covariance matrix.", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.212", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-18.520", "ciUpperLimit": "16.096", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "10.317"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Asthma Control Questionnaire (ACQ)-5 Score at Week 1, Week 2, Week 3, and Week 4", "description": "The 5-question version of the Juniper ACQ is a validated questionnaire to evaluate asthma control. Questions were weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The mean ACQ score was the mean of the responses. Mean scores of \\<= 0.75 indicate well-controlled asthma, scores between 0.76 and less than (\\<) 1.5 indicate partly controlled asthma, and a score \\>= 1.5 indicates uncontrolled asthma.", "populationDescription": "The mITT analysis set included all randomized participants who received at least 1 dose of PF-03715455 or placebo; n=number of participants analyzed in respective arms for category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, Week 1, Week 2, Week 3, and Week 4", "groups": [{"id": "OG000", "title": "Placebo Twice Daily", "description": "Participants received placebo-matched PF-03715455 twice a day for 12 weeks via oral inhalation using the Miat monodose inhaler."}, {"id": "OG001", "title": "PF-03715455 680 mcg Twice Daily", "description": "Participants received PF-03715455 680 micrograms (mcg) twice a day for 12 weeks via oral inhalation using the Miat monodose inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "25"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "25"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.18", "spread": "0.315"}, {"groupId": "OG001", "value": "2.17", "spread": "0.489"}]}]}, {"title": "Change at Week 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "25"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.50", "spread": "0.742"}, {"groupId": "OG001", "value": "-0.27", "spread": "0.658"}]}]}, {"title": "Change at Week 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "23"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.66", "spread": "0.826"}, {"groupId": "OG001", "value": "-0.53", "spread": "0.670"}]}]}, {"title": "Change at Week 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "20"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.62", "spread": "0.959"}, {"groupId": "OG001", "value": "-0.34", "spread": "0.751"}]}]}, {"title": "Change at Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "21"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.71", "spread": "0.838"}, {"groupId": "OG001", "value": "-0.41", "spread": "0.806"}]}]}]}, {"type": "SECONDARY", "title": "Number of Daily Puffs of Rescue Medication", "description": "The use of rescue bronchodilators (albuterol or levalbuterol) for symptomatic relief of asthma in a 24-hour period was recorded by the participant.", "populationDescription": "The mITT analysis set included all randomized participants who received at least 1 dose of PF-03715455 or placebo; n=number of participants analyzed in respective arms for category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "puffs per day", "timeFrame": "Baseline, Week 1, Week 2, Week 3, and Week 4", "groups": [{"id": "OG000", "title": "Placebo Twice Daily", "description": "Participants received placebo-matched PF-03715455 twice a day for 12 weeks via oral inhalation using the Miat monodose inhaler."}, {"id": "OG001", "title": "PF-03715455 680 mcg Twice Daily", "description": "Participants received PF-03715455 680 micrograms (mcg) twice a day for 12 weeks via oral inhalation using the Miat monodose inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "25"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "25"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.90", "spread": "1.364"}, {"groupId": "OG001", "value": "1.96", "spread": "1.628"}]}]}, {"title": "Week 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "25"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.51", "spread": "1.254"}, {"groupId": "OG001", "value": "1.74", "spread": "2.164"}]}]}, {"title": "Week 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "23"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.51", "spread": "1.431"}, {"groupId": "OG001", "value": "1.07", "spread": "1.494"}]}]}, {"title": "Week 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "20"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.48", "spread": "1.391"}, {"groupId": "OG001", "value": "1.37", "spread": "1.772"}]}]}, {"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "21"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.34", "spread": "1.385"}, {"groupId": "OG001", "value": "1.54", "spread": "2.264"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Baseline up to 1 month after end-of-treatment visit (Week 12)", "eventGroups": [{"id": "EG000", "title": "Placebo Twice Daily", "description": "Participants received placebo-matched PF-03715455 twice a day for 12 weeks via oral inhalation using the Miat monodose inhaler.", "seriousNumAffected": 0, "seriousNumAtRisk": 26, "otherNumAffected": 10, "otherNumAtRisk": 26}, {"id": "EG001", "title": "PF-03715455 680 mcg Twice Daily", "description": "Participants received PF-03715455 680 micrograms (mcg) twice a day for 12 weeks via oral inhalation using the Miat monodose inhaler.", "seriousNumAffected": 0, "seriousNumAtRisk": 25, "otherNumAffected": 15, "otherNumAtRisk": 25}], "otherEvents": [{"term": "Dry eye", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 25}]}, {"term": "Gingival hypertrophy", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 25}]}, {"term": "Toothache", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 25}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 25}]}, {"term": "Influenza-like illness", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 25}]}, {"term": "Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 25}]}, {"term": "Acute sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 25}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 25}]}, {"term": "Conjunctivitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 25}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 25}]}, {"term": "Gastroenteritis viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 25}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 25}]}, {"term": "Oral herpes", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 25}]}, {"term": "Respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 25}]}, {"term": "Skin infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 25}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 25}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 25}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 25}]}, {"term": "Mouth injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 25}]}, {"term": "Blood creatine phosphokinase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 25}]}, {"term": "Blood urine present", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 25}]}, {"term": "Forced expiratory volume decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 25}]}, {"term": "Hepatic enzyme increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 25}]}, {"term": "Costochondritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 25}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 25}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 25}]}, {"term": "Dysgeusia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 25}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 25}]}, {"term": "Migraine", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 25}]}, {"term": "Middle insomnia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 25}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 25}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 25}]}, {"term": "Nasal oedema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 25}]}, {"term": "Pharyngeal mass", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 25}]}, {"term": "Productive cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 25}]}, {"term": "Rhinitis allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 25}]}, {"term": "Sinus congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 25}]}, {"term": "Oral candidiasis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 25}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 25}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 25}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 25}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 25}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "The study was terminated early due to portfolio prioritization. Most participants observations of time to asthma worsening event were censored by the study termination."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."}, "pointOfContact": {"title": "Pfizer ClinicalTrials.gov Call Center", "organization": "Pfizer, Inc.", "email": "ClinicalTrials.gov_Inquiries@pfizer.com", "phone": "1-800-718-1021"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}}, "hasResults": true}